Suzhou Canimble Biotechnology Co., Ltd.

Suzhou Kanebo Biotechnology Co., Ltd. was established in November 2011. The company is located in Phoenix Science and Technology Entrepreneurship Park, Zhangjiagang City, Jiangsu Province. It currently has a 2,000-square-meter standardized R&D center and a 200-acre production base. The founder was selected as one of the first batch of high-level leading innovative and entrepreneurial talents in Zhangjiagang City in 2012. The core technical team currently consists of 3 doctors and 8 masters. The company's project was rated as a key recommended project for leading talents in 2012, the first prize of the 2013 Suzhou Youth Elite Entrepreneurship Competition, and the second prize of the first Jiangsu Province Innovation and Entrepreneurship Competition. The company's main business includes: 1. Development and production of key intermediates for a full range of anti-tumor drugs; 2. Provide technical development and production support for pharmaceutical intermediates and APIs for large domestic and foreign pharmaceutical companies; 3. The synthetic application of ketoreductase in chiral drugs, with bio-enzyme technology as the core, solves the bottleneck and environmental pressure of chemical production of some chiral intermediates. In the practice of market competition, Kanebo Bio insists on taking scientific and technological innovation as the driving force and is committed to building the core competitiveness of the enterprise. The company plans to introduce 30 high-end technical talents, and maintain technical exchanges and cooperation with Hengrui's National Targeted Drug Engineering Technology Research Center, Nanjing Xiansheng Pharmaceutical Research Institute, and the Oncology Department of the Centers for Disease Control and Prevention (CDC). After the establishment of the company, it has applied for more than ten invention patents, and the patent for the active molecular model of small molecule targeted tumor drugs is applying for an international patent. Kanebo Bio adheres to the concept of "creating unlimited possibilities for medical technology and developing high-end biochemical industry", strives for progress, dares to innovate, and continuously achieves leaps and breakthroughs in corporate development.